Clinical trials: Diabetes Mellitus Progression
Diabetes, Inflammation
Vascular Risk Progression in Normal and Diabetic Control Subjects.
The purpose of this study is to look at the progression of cardiovascular disease (CVD) in normal control individuals and in patients with controlled diabetes.
- Trial name
- NCT00579228
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Obesity, Visceral, Chronic Kidney Diseases
The Association of Visceral Adiposity Index With Progression of Chronic Kidney Disease
The visceral adiposity index (VAI) has been developed, an indicator for the metabolic function of VAT. Previous studies have confirmed the association between the VAI and CKD prevalence.
- Conditions
- Obesity, Visceral, Chronic Kidney Diseases, Diabetes Mellitus
- Trial name
- NCT04592107
- Testing
- eGFR
- Where
- Turkey (Türkiye)
- Volunteers
- 129 people
- Sponsor
- Uşak University
Carotid Atherosclerosis
Carotid Atherosclerosis and Vascular Events in People With Diabetes
Diabetes is a risk factor for carotid atherosclerotic whose progression is associated with an increased risk of vascular events.
- Trial name
- PROCAVE-D (NCT02929355)
- Testing
- carotid assesment by duplex ultrasonography
- Where
- France
- Volunteers
- 731 people
- Sponsor
- Hospices Civils de Lyon
PD-(L)1, CTLA-4
Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study
Several studies have shown that the combination of Iparomlimab, Tuvonralimab, and Bevacizumab exhibits potent anti-tumor activity and favorable safety in various solid tumors, including liver cancer.
- Conditions
- PD-(L)1, CTLA-4, Advanced Melanoma, Iparomlimab
- Trial name
- NCT07004335
- Testing
- Iparomlimab and Tuvonralimab Injection plus Bevacizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Hebei Medical University Fourth Hospital
Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1
Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on progression of coronary atherosclerosis in patients with type 2 diabetes.
- Trial name
- NCT03602638
- Testing
- Sitagliptin, Acarbose
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Diabetic Foot Ulcer, Non-healing Wound
Debritom - Micro Water Jet Technology and Wound Healing
This study will investigate the clinical efficacy of micro water jet technology in the debridement and healing of chronic lower extremity ulcers.
- Conditions
- Diabetic Foot Ulcer, Non-healing Wound, Non-Healing Ulcer of Skin, Venous Leg Ulcer
- Trial name
- NCT04240574
- Testing
- Debritom
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stephanie Wu
Diabetes
RetroMASTER - Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes
This study will examine extreme responders to second- and third-line Type 2 Diabetes (T2D) therapy using a retrospective approach and patients with slow or fast diabetes progression.
- Trial name
- RetroMASTER (NCT02109978)
- Where
- 3 sites in United Kingdom
- Volunteers
- 562 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Obesity and Type 2 Diabetes
Role of KATP Channel Loss in Type 2 Diabetes
Insulin is a hormone that is made by β-cells in the pancreas and when released into the bloodstream helps control blood sugar levels.
- Trial name
- BC (NCT06830096)
- Testing
- 10 mg glipizide ingestion
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine